Breaking News Instant updates and real-time market news.

ADAP

Adaptimmune

$0.71

-0.0959 (-11.87%)

12:51
11/17/19
11/17
12:51
11/17/19
12:51

Adaptimmune data confirms ADP-A2M4 delivers clinical benefit

Adaptimmune Therapeutics presented updated data from people with synovial sarcoma treated in the ongoing Phase 1 trial with ADP-A2M4. The oral presentation by Brian Van Tine, MD, PhD of Washington University School of Medicine in St. Louis, took place at the Connective Tissue Oncology Society, or CTOS, annual meeting in Tokyo, Japan. The presentation was an update of the data that Dr. Van Tine presented at ESMO on September 30. Out of the 14 patients with synovial sarcoma who have been treated in the expansion phase of this trial and have post-baseline scans, to date, seven have had clinical responses, representing an overall response rate of 50%. Thirteen patients showed clinical benefit with best overall responses of PR or stable disease - representing a disease control rate of 93%. "This updated data set confirms that ADP-A2M4 continues to deliver clinical benefit, including RECIST responses, to patients with synovial sarcoma. It has also galvanized the support we have received from the sarcoma community, allowing us to rapidly open multiple sites and screen patients for the Phase 2 SPEARHEAD-1 trial," said Elliot Norry, Adaptimmune's acting Chief Medical Officer. "We expect that all sites for SPEARHEAD-1 will be open by the end of the first quarter in 2020, marking another step toward our goal of making this treatment available commercially to people with sarcoma in 2022."

ADAP Adaptimmune
$0.71

-0.0959 (-11.87%)

08/01/19
GUGG
08/01/19
DOWNGRADE
GUGG
Neutral
Adaptimmune downgraded to Neutral from Buy at Guggenheim
Guggenheim analyst Michael Schmidt downgraded Adaptimmune to Neutral from Buy.
08/02/19
GUGG
08/02/19
DOWNGRADE
GUGG
Neutral
Adaptimmune downgraded to Neutral on low near-term visibility at Guggenheim
As previously reported, Guggenheim analyst Michael Schmidt downgraded Adaptimmune to Neutral from Buy as he believes visibility into the opportunity for the company's pipeline remains limited, particularly following discontinuation of the MAGEA10 program, reports of 3 new patient deaths, and resignation of the company's CMO. Additionally, financing needs may be an overhang, said Schmidt. While results to date for MAGE-A4 in synovial sarcoma "look intriguing," its commercial opportunity is small, added Schmidt.
08/02/19
08/02/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Oshkosh (OSK) downgraded to Sector Weight from Overweight at KeyBanc with analyst Steve Barger saying that while he thinks Oshkosh is a better story than some other machinery names given solid execution and the potential for some growth or at least stability from its non- Access segments, he sees more room for negative catalysts than positive due to the deceleration in macro data, a growing view that AWP will be flat-to-down next year, and order and backlog contraction against a tough comp from FY19. 2. Square (SQ) downgraded to Underperform from Outperform at Evercore ISI. 3. Adaptimmune (ADAP) downgraded to Neutral from Buy at Guggenheim with analyst Michael Schmidt saying he believes visibility into the opportunity for the company's pipeline remains limited, particularly following discontinuation of the MAGEA10 program, reports of 3 new patient deaths, and resignation of the company's CMO. 4. Hilton Grand Vacations (HGV) downgraded to Underweight from Neutral at JPMorgan with analyst Brandt Montour saying he expects poor sentiment to weigh on shares until the company's contract sales reaccelerate in a consistent way, which he feels is not likely until 2020. 5. Valaris (VAL) downgraded to Market Perform from Outperform at Wells Fargo with analyst Coleman Sullivan saying he reduced his EBITDA forecasts through 2021 to account for revised rig startup assumptions, more conservative utilization and dayrate assumptions on floaters and revised cost assumptions. Sullivan, who continues to be disappointed by the lack of contracts at rates peers are able to achieve, sees the company's outlook having more inherent risk going forward. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/23/19
10/23/19
NO CHANGE

Adaptimmune management to meet with SunTrust
Meeting to be held in Texas October 23 hosted by SunTrust.

TODAY'S FREE FLY STORIES

AUTL

Autolus Therapeutics

$14.60

-0.18 (-1.22%)

07:19
12/09/19
12/09
07:19
12/09/19
07:19
Conference/Events
Autolus Therapeutics to host conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 09

    Dec

SPCE

Virgin Galactic

$7.28

0.07 (0.97%)

07:17
12/09/19
12/09
07:17
12/09/19
07:17
Initiation
Virgin Galactic initiated  »

Morgan Stanley cites…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

TCBI

Texas Capital

$57.82

0.76 (1.33%)

, IBTX

Independent Bank

$59.23

1 (1.72%)

07:15
12/09/19
12/09
07:15
12/09/19
07:15
Hot Stocks
Independent Bank, Texas Capital Bancshares enter $5.5B all-stock merger »

Texas Capital Bancshares…

TCBI

Texas Capital

$57.82

0.76 (1.33%)

IBTX

Independent Bank

$59.23

1 (1.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZLAB

Zai Lab

$41.25

0.11 (0.27%)

07:15
12/09/19
12/09
07:15
12/09/19
07:15
Recommendations
Zai Lab analyst commentary  »

Citi opens 'positive…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PEGI

Pattern Energy

$27.45

0.02 (0.07%)

07:14
12/09/19
12/09
07:14
12/09/19
07:14
Hot Stocks
Pattern Energy announces expiration of 'Go-Shop Period' »

Pattern Energy announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MMM

3M

$171.49

7.13 (4.34%)

07:12
12/09/19
12/09
07:12
12/09/19
07:12
Downgrade
3M rating change  »

Citi downgrades 3M to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

FTV

Fortive

$72.86

0.5 (0.69%)

, MMM

3M

$171.49

7.13 (4.34%)

07:11
12/09/19
12/09
07:11
12/09/19
07:11
Upgrade
Fortive, 3M rating change  »

Citi upgrades Fortive to…

FTV

Fortive

$72.86

0.5 (0.69%)

MMM

3M

$171.49

7.13 (4.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 10

    Dec

ORAN

Orange SA

$15.02

-0.055 (-0.36%)

07:10
12/09/19
12/09
07:10
12/09/19
07:10
Downgrade
Orange SA rating change  »

Orange SA downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KMDA

Kamada

$7.36

-0.025 (-0.34%)

07:10
12/09/19
12/09
07:10
12/09/19
07:10
Hot Stocks
Kamada enters into binding term sheet, sees product adding $8M-$10M in revenue »

Kamada announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSIQ

Canadian Solar

$18.35

0.39 (2.17%)

07:09
12/09/19
12/09
07:09
12/09/19
07:09
Hot Stocks
Canadian Solar authorizes $150M share repurchase program »

Canadian Solar announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ETNB

89bio

$28.38

0.86 (3.13%)

07:09
12/09/19
12/09
07:09
12/09/19
07:09
Initiation
89bio initiated  »

89bio initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SONG

Akazoo

$5.40

-0.12 (-2.17%)

07:08
12/09/19
12/09
07:08
12/09/19
07:08
Earnings
Akazoo reports Q3 EPS EUR0.03 vs, EUR0.02 last year »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ECC

Eagle Point Credit

$15.03

-0.01 (-0.07%)

07:08
12/09/19
12/09
07:08
12/09/19
07:08
Upgrade
Eagle Point Credit rating change  »

Eagle Point Credit…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TXN

Texas Instruments

$122.36

1.6 (1.32%)

07:07
12/09/19
12/09
07:07
12/09/19
07:07
Conference/Events
Texas Instruments management to meet with UBS »

Dinner Meeting with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 09

    Dec

  • 16

    Dec

KALV

KalVista

$14.36

0.25 (1.77%)

, MRK

Merck

$88.84

0.09 (0.10%)

07:06
12/09/19
12/09
07:06
12/09/19
07:06
Hot Stocks
KalVista says KVD001 does not meet primary endpoint »

KalVista Pharmaceuticals…

KALV

KalVista

$14.36

0.25 (1.77%)

MRK

Merck

$88.84

0.09 (0.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 11

    Dec

  • 24

    Jan

  • 24

    Jan

  • 05

    Feb

  • 14

    Mar

VTNR

Vertex Energy

$1.59

(0.00%)

07:05
12/09/19
12/09
07:05
12/09/19
07:05
Initiation
Vertex Energy initiated  »

Vertex Energy initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

T

AT&T

$38.20

-0.01 (-0.03%)

07:05
12/09/19
12/09
07:05
12/09/19
07:05
Conference/Events
AT&T management to meet with UBS »

Dinner Meeting with CEO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 09

    Dec

  • 29

    Jan

NOW

ServiceNow

$272.19

-0.94 (-0.34%)

07:03
12/09/19
12/09
07:03
12/09/19
07:03
Conference/Events
ServiceNow management to meet with UBS »

Dinner Meeting with Chief…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 09

    Dec

  • 12

    Dec

RCKT

Rocket Pharmaceuticals

$22.37

2.61 (13.21%)

07:03
12/09/19
12/09
07:03
12/09/19
07:03
Hot Stocks
Rocket Pharmaceuticals announces preliminary data from RP-L201 Phase 1/2 trial »

Rocket Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AGIO

Agios Pharmaceuticals

$40.93

0.81 (2.02%)

07:03
12/09/19
12/09
07:03
12/09/19
07:03
Recommendations
Agios Pharmaceuticals analyst commentary  »

Cantor sees Agios trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 13

    Dec

AGIO

Agios Pharmaceuticals

$40.93

0.81 (2.02%)

07:01
12/09/19
12/09
07:01
12/09/19
07:01
Recommendations
Agios Pharmaceuticals analyst commentary  »

Agios Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 13

    Dec

CI

Cigna

$198.96

3.44 (1.76%)

07:00
12/09/19
12/09
07:00
12/09/19
07:00
Conference/Events
Cigna management to meet with Stephens »

Group Luncheon Meeting…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 06

    Feb

AMAT

Applied Materials

$56.60

0.77 (1.38%)

06:59
12/09/19
12/09
06:59
12/09/19
06:59
Conference/Events
Applied Materials management to meet with UBS »

Breakfast Meeting with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

CGC

Canopy Growth

$18.65

0.07 (0.38%)

, STZ

Constellation Brands

$183.60

1.13 (0.62%)

06:58
12/09/19
12/09
06:58
12/09/19
06:58
Recommendations
Cantor sees over 66% chance of Constellation bidding for Canopy Growth »

Cantor Fitzgerald analyst…

CGC

Canopy Growth

$18.65

0.07 (0.38%)

STZ

Constellation Brands

$183.60

1.13 (0.62%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Jan

MTG

MGIC Investment

$14.10

-0.03 (-0.21%)

06:58
12/09/19
12/09
06:58
12/09/19
06:58
Hot Stocks
MGIC Investment issues November operating statistics »

MGIC Investment issued an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.